Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
135.4 USD | -0.91% | -2.86% | +2.77% |
May. 31 | Neurocrine Biosciences Insider Sold Shares Worth $5,338,565, According to a Recent SEC Filing | MT |
May. 28 | Neurocrine Biosciences Says CEO Kevin Gorman Retiring | MT |
Evolution of the average Target Price on Neurocrine Biosciences, Inc.
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering Neurocrine Biosciences, Inc.
UBS | |
Oppenheimer | |
Wells Fargo Securities | |
Morgan Stanley | |
JPMorgan Chase | |
Deutsche Bank Securities | |
Citigroup | |
Mizuho Securities | |
Wedbush | |
Goldman Sachs | |
Barclays | |
RBC Capital Markets | |
Stifel Nicolaus | |
Piper Sandler | |
Raymond James | |
Jefferies & Co. | |
HC Wainwright | |
Canaccord Genuity | |
BMO Capital | |
Baird | |
Guggenheim | |
Evercore ISI | |
SVB Securities LLC | |
Royal Bank of Canada | |
Cantor Fitzgerald | |
J.P. Morgan Chase | |
SVB Leerink | |
Credit Suisse |
EPS Revisions
- Stock Market
- Equities
- NBIX Stock
- Consensus Neurocrine Biosciences, Inc.